EP1694315A4 - Glykopegylierter faktor ix - Google Patents
Glykopegylierter faktor ixInfo
- Publication number
- EP1694315A4 EP1694315A4 EP04813394A EP04813394A EP1694315A4 EP 1694315 A4 EP1694315 A4 EP 1694315A4 EP 04813394 A EP04813394 A EP 04813394A EP 04813394 A EP04813394 A EP 04813394A EP 1694315 A4 EP1694315 A4 EP 1694315A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- glycopegylated factor
- glycopegylated
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229960004222 factor ix Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52708903P | 2003-12-03 | 2003-12-03 | |
US53938704P | 2004-01-26 | 2004-01-26 | |
US59274404P | 2004-07-29 | 2004-07-29 | |
US61451804P | 2004-09-29 | 2004-09-29 | |
US62338704P | 2004-10-29 | 2004-10-29 | |
PCT/US2004/041070 WO2005055950A2 (en) | 2003-12-03 | 2004-12-03 | Glycopegylated factor ix |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1694315A2 EP1694315A2 (de) | 2006-08-30 |
EP1694315A4 true EP1694315A4 (de) | 2009-10-28 |
Family
ID=34682416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04813394A Withdrawn EP1694315A4 (de) | 2003-12-03 | 2004-12-03 | Glykopegylierter faktor ix |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1694315A4 (de) |
JP (1) | JP4738346B2 (de) |
KR (1) | KR101209111B1 (de) |
AU (1) | AU2004296860B2 (de) |
BR (1) | BRPI0417341A (de) |
CA (1) | CA2549413A1 (de) |
IL (1) | IL175661A0 (de) |
MX (1) | MXPA06006023A (de) |
NZ (1) | NZ546733A (de) |
WO (1) | WO2005055950A2 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
CN102212019B (zh) | 2003-03-14 | 2015-05-27 | 蔚所番有限公司 | 支化水溶性聚合物及其缀合物 |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
EP2055189A1 (de) | 2003-04-09 | 2009-05-06 | Neose Technologies, Inc. | Glycopegylierungsverfahren und durch die Verfahren hergestellte Proteine/Peptide |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
CA2552892C (en) | 2004-01-08 | 2014-08-05 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
AU2005260763B2 (en) * | 2004-06-30 | 2011-12-22 | Nektar Therapeutics | Polymer-factor IX moiety conjugates |
AU2014280936B2 (en) * | 2004-06-30 | 2016-12-15 | Nektar Therapeutics | Polymer-factor ix moiety conjugates |
EP1771066A2 (de) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Remodellierung von verzweigtem peg und klykolysierung von glucagonähnlichem peptide-1 glp-1 |
WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
EP3061461A1 (de) | 2004-10-29 | 2016-08-31 | ratiopharm GmbH | Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf) |
EP2514757A3 (de) | 2005-01-10 | 2014-03-05 | ratiopharm GmbH | Glycopegylierter Granulozyten-Kolonie stimulierende Faktor |
EP2386571B1 (de) | 2005-04-08 | 2016-06-01 | ratiopharm GmbH | Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons |
EP2975135A1 (de) * | 2005-05-25 | 2016-01-20 | Novo Nordisk A/S | Glykopegylierter Faktor IX |
EP1937719A4 (de) * | 2005-08-19 | 2010-11-24 | Novo Nordisk As | Glycopegylierter faktor vii und faktor viia |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
EP2049144B8 (de) * | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylierung von peptiden über o-verbundene glycosylierungssequenzen |
US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
WO2008060780A2 (en) * | 2006-10-04 | 2008-05-22 | Novo Nordisk A/S | Glycerol linked pegylated sugars and glycopeptides |
BRPI0720282B8 (pt) | 2006-12-15 | 2021-05-25 | Baxalta GmbH | construção proteica, composição farmacêutica, e, kit |
KR20150064246A (ko) | 2007-04-03 | 2015-06-10 | 바이오제너릭스 게엠베하 | 글리코페길화 g―csf를 이용하는 치료 방법 |
WO2008134665A1 (en) * | 2007-04-26 | 2008-11-06 | Inspiration Biopharmaceuticals, Inc. | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same |
CN101778859B (zh) | 2007-06-12 | 2014-03-26 | 诺和诺德公司 | 改良的用于生产核苷酸糖的方法 |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
CN102026653B (zh) * | 2007-10-15 | 2014-06-18 | 北卡罗来纳-查佩尔山大学 | 半衰期延长的人因子ⅸ变体 |
CA2709960A1 (en) * | 2007-12-27 | 2009-07-09 | Baxter International Inc. | Chemically modified factor ix |
KR101582841B1 (ko) | 2008-02-27 | 2016-01-11 | 노보 노르디스크 에이/에스 | 콘쥬게이트된 인자 viii 분자 |
SG189790A1 (en) * | 2008-04-16 | 2013-05-31 | Bayer Healthcare Llc | Modified factor ix polypeptides and uses thereof |
RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
AU2010277438B2 (en) | 2009-07-27 | 2015-08-20 | Baxalta GmbH | Glycopolysialylation of non-blood coagulation proteins |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
DK2459224T3 (en) | 2009-07-27 | 2016-07-25 | Baxalta GmbH | Blodstørkningsproteinkonjugater |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
BR112012002072A2 (pt) * | 2009-07-31 | 2016-11-08 | Bayer Healthcare Llc | polipeptídeos de fator ix modificados e usos dos mesmos |
CN107383158A (zh) | 2009-11-24 | 2017-11-24 | 诺沃—诺迪斯克保健股份有限公司 | 纯化聚乙二醇化蛋白质的方法 |
CN103140237A (zh) | 2010-07-09 | 2013-06-05 | 比奥根艾迪克依蒙菲利亚公司 | 因子ix多肽及其使用方法 |
PL2654794T3 (pl) | 2010-12-22 | 2020-07-27 | Baxalta GmbH | Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem |
TW201519900A (zh) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法 |
CN117603949A (zh) | 2019-03-19 | 2024-02-27 | 杰特创新股份有限公司 | 因子ix变体及其在治疗中的用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59172425A (ja) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
EP1260582A1 (de) * | 1995-09-29 | 2002-11-27 | Biovitrum Ab | Konjugate von Faktor IX und einem biologisch verträglichen Polymer |
WO2003031464A2 (en) * | 2001-10-10 | 2003-04-17 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA00005376A (es) * | 1997-12-01 | 2002-07-02 | Neose Technologies Inc | Sintesis enzimatica de gangliosidos. |
-
2004
- 2004-12-03 AU AU2004296860A patent/AU2004296860B2/en not_active Ceased
- 2004-12-03 WO PCT/US2004/041070 patent/WO2005055950A2/en active Application Filing
- 2004-12-03 CA CA002549413A patent/CA2549413A1/en not_active Abandoned
- 2004-12-03 EP EP04813394A patent/EP1694315A4/de not_active Withdrawn
- 2004-12-03 BR BRPI0417341-4A patent/BRPI0417341A/pt not_active Application Discontinuation
- 2004-12-03 NZ NZ546733A patent/NZ546733A/en not_active IP Right Cessation
- 2004-12-03 JP JP2006542888A patent/JP4738346B2/ja not_active Expired - Fee Related
- 2004-12-03 MX MXPA06006023A patent/MXPA06006023A/es active IP Right Grant
-
2006
- 2006-05-16 IL IL175661A patent/IL175661A0/en unknown
- 2006-05-30 KR KR1020067010603A patent/KR101209111B1/ko not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59172425A (ja) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
EP1260582A1 (de) * | 1995-09-29 | 2002-11-27 | Biovitrum Ab | Konjugate von Faktor IX und einem biologisch verträglichen Polymer |
WO2003031464A2 (en) * | 2001-10-10 | 2003-04-17 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
Non-Patent Citations (1)
Title |
---|
DUDZIAK G ET AL: "Cyclodextrin-assisted Glycan Chain Extension on a Protected Glycosyl Amino Acid", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 56, no. 32, 4 August 2000 (2000-08-04), pages 5865 - 5869, XP004229184, ISSN: 0040-4020 * |
Also Published As
Publication number | Publication date |
---|---|
JP2007513190A (ja) | 2007-05-24 |
EP1694315A2 (de) | 2006-08-30 |
BRPI0417341A (pt) | 2007-04-17 |
KR101209111B1 (ko) | 2012-12-06 |
KR20060123224A (ko) | 2006-12-01 |
WO2005055950A3 (en) | 2005-10-20 |
WO2005055950A2 (en) | 2005-06-23 |
JP4738346B2 (ja) | 2011-08-03 |
AU2004296860B2 (en) | 2010-04-22 |
AU2004296860A1 (en) | 2005-06-23 |
IL175661A0 (en) | 2006-09-05 |
CA2549413A1 (en) | 2005-06-23 |
NZ546733A (en) | 2009-07-31 |
MXPA06006023A (es) | 2006-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1694315A4 (de) | Glykopegylierter faktor ix | |
LU92773I2 (fr) | Sécukinumab | |
DE502004003292D1 (de) | Flugzeug | |
IS2875B (is) | Pýrasólópýridínafleiður | |
DE602004011161D1 (de) | Kraftfahrzeugschliessanlage | |
IS8412A (is) | Kínasólínafleiður | |
DE602004004904D1 (de) | Nuancierungsmittel | |
DE60332056D1 (de) | Signalformverschlechterungskompensator | |
SE0302091L (sv) | Genomföring | |
DE502004007911D1 (de) | Wischblatt | |
NO20043452L (no) | Bronnreguleringsutstyr | |
FI20031741A (fi) | Liukukäytävä | |
DE60313598D1 (de) | Verzögerungszeitdiskriminator | |
ATA662003A (de) | Trink-mundstück | |
DE502004003823D1 (de) | Kran | |
FI6176U1 (fi) | Spraypäällystysyksikkö | |
ITMI20032432A1 (it) | Pentola | |
DE502004002978D1 (de) | N-biarylamide | |
DE602004010064D1 (de) | Freilaufkupplungsfeder | |
DE502004010244D1 (de) | En | |
ZA200706129B (en) | Glycopegylated Factor IX | |
FI20035015A0 (fi) | Kuljetuskontti | |
EP1639260A4 (de) | Hochdruckdosierventil | |
DE602004026432D1 (de) | Ntalschicht | |
DE60310615D1 (de) | Abschreckflüssigkeitzusammensetzung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060630 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
RAX | Requested extension states of the european patent have changed |
Extension state: HR Payment date: 20060731 |
|
RAX | Requested extension states of the european patent have changed |
Extension state: HR Payment date: 20060731 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NEOSE TECHNOLOGIES, INC. |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NOVO NORDISK A/S |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090924 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/48 20060101AFI20090918BHEP Ipc: C07K 14/745 20060101ALI20090918BHEP |
|
17Q | First examination report despatched |
Effective date: 20101029 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160502 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20160914 |